Name: 4D-150 in Neovascular age-related macular degeneration: Administration
Published: 2026-09-17T18:33:01-04:00

Product information and disease description Product description Product information Dosing and administration

Administration

3 evidence topics · 6 sources

Route and care setting

“The product candidate combines our proprietary R100 vector designed for efficient intravitreal delivery to the retina with a dual transgene payload expressing aflibercept and VEGF-C RNAi.” (opens the source at this quote in a new tab)
“Intravitreal delivery of biologics into the eye is a routine in-office injection, which we believe allows for seamless adoption into retina clinic workflows.” (opens the source at this quote in a new tab)

Topical corticosteroid prophylaxis regimen in the PRISM clinical trial

“14/15 participants did not require steroids after completion of the protocol-mandated 20-week prophylactic topical steroid taper” (opens the source at this quote in a new tab)

“97% (38 of 39) completed the 20-week topical corticosteroid taper on schedule; no participant restarted steroids during up to 48 weeks of follow up” (opens the source at this quote in a new tab)

“99% (70 of 71) completed steroid prophylaxis taper on schedule” (opens the source at this quote in a new tab)

Aflibercept loading doses administered around 4D-150 dosing

“All patients randomized to receive 3 total loading doses per aflibercept label” (opens the source at this quote in a new tab)

“Aflibercept 2mg dosed at Day -7 and Day 28. 4D-150 dosed at Day 0.” (opens the source at this quote in a new tab)